SYMBIOTEC vs VAISHALI: Stock Comparison
SYMBIOTEC PHARMALAB is the larger company by market capitalisation. VAISHALI PHARMA shows faster revenue growth and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
SYMBIOTEC leads 1; VAISHALI leads 2 of 4
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | SYMBIOTEC | VAISHALI |
|---|---|---|
| Sector | — | Healthcare |
| Industry | — | Pharmaceuticals |
Price
| Metric | SYMBIOTEC | VAISHALI |
|---|---|---|
| Live Price | ₹1,038.6 | ₹8.8 |
| Day Change | -0.4% | 1.38% |
| Volume | 2.75 L | 57,907 |
| 52-Week High | ₹1,193.7 | ₹12.7 |
| 52-Week Low | ₹934.2 | ₹4.75 |
| Distance from 52W High | -12.99% | -30.71% |
Valuation
| Metric | SYMBIOTEC | VAISHALI |
|---|---|---|
| Market Cap | ₹6,624 Cr | ₹114 Cr |
| EPS | — | ₹0.11 |
| Book Value | — | ₹5.3 |
| Dividend Yield | 0% | 0% |
Growth
| Metric | SYMBIOTEC | VAISHALI |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | 18.35% |
| EPS Growth (TTM YoY) | 0% | -76.71% |
| Qtr Sales Growth | — | 0% |
| Qtr Profit Growth | — | -3.65% |
Profitability & Leverage
| Metric | SYMBIOTEC | VAISHALI |
|---|---|---|
| ROE | — | 6.03% |
| ROCE | — | 6.36% |
| Net Margin | 0% | 3.83% |
| Operating Margin | — | 6.76% |
| Debt to Equity | — | 0.27x |
Shareholding
As of Aug 2026 • change vs previous quarter| Metric | SYMBIOTEC | VAISHALI |
|---|---|---|
| Promoter Holding | 33.28% | 31.61% |
| FII Holding | 21.08% | 0% |
| DII Holding | 27.52% | 0% |
| Public Holding | 18.12% | 68.39% |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: SYMBIOTEC PHARMALAB and VAISHALI PHARMA.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.